Is the Market Bullish or Bearish on Krystal Biotech?
According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...
Zacks.com on MSN19h
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $2,869.50 today based on a price of $178.29 for KRYS at the time of writing.
PMLiVE22h
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Hosted on MSN20h
LGND: First Steps into Cell & Gene Therapy
LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
BioPharma Dive21h
Biotech M&A has plateaued. Track the deals that are happening here.
In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Finally, BioPharma Dive updates the tracker when deals are ...